COMPUGROUP MEDICAL: Growth prospects are now well priced in – downgrade to Neutral | NEUTRAL vs. BUY | EUR87 VS. EUR78 (+7%)
COMPUGROUP MEDICAL - NEUTRAL vs. BUY | EUR87 VS. EUR78 (+7%)Growth prospects are now well priced in – downgrade to Neutral
H2 to be slower than H1
Recent stock performance means a limited upside potential remains
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.